一项针对患有至少一种与体重相关的合并症的肥胖或超重参与者的研究 (APRICUS)
一项 IIb 期随机、双盲、安慰剂对照研究,旨在评估 AZD6234 对肥胖或超重合并症参与者的有效性、安全性和耐受性
A Phase IIb Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of AZD6234 compared with placebo, given once a week as subcutaneous injection for 36 weeks, in male and female participants of at least 18 years of age who are living with obesity (body mass index [BMI] ≥ 30 kg/m2), or overweight (BMI ≥ 27 kg/m2) and at least one weight-related comorbidity
研究概览
详细说明
The study will comprise of:
A screening period of maximum 28 days
A treatment period of 36 weeks
A follow up period after last dose of study drug
This study will consist of 4 cohorts. Approximately 231 eligible participants will be randomized to AZD6234 or placebo
研究类型
注册 (实际的)
阶段
- 阶段2
联系人和位置
学习地点
-
-
Ontario
-
Hamilton、Ontario、加拿大、L8L 5G8
- Research Site
-
Sarnia、Ontario、加拿大、N7T 4X3
- Research Site
-
Stouffville、Ontario、加拿大、L4A1H2
- Research Site
-
Toronto、Ontario、加拿大、M3J 0K2
- Research Site
-
-
Quebec
-
Montreal、Quebec、加拿大、H4N 2W2
- Research Site
-
Sherbrooke、Quebec、加拿大、J1L 0H8
- Research Site
-
-
-
-
-
Chūōku、日本、103-0027
- Research Site
-
Chūōku、日本、104-0031
- Research Site
-
Shinjuku-ku、日本、160-0008
- Research Site
-
Suita-shi、日本、565-0853
- Research Site
-
-
-
-
-
Heidelberg、澳大利亚、3081
- Research Site
-
Maroochydore、澳大利亚、4556
- Research Site
-
Maroubra、澳大利亚、2035
- Research Site
-
Merewether、澳大利亚、2291
- Research Site
-
-
-
-
Alabama
-
Mobile、Alabama、美国、36608
- Research Site
-
-
Arizona
-
Phoenix、Arizona、美国、85044
- Research Site
-
-
California
-
Long Beach、California、美国、90815
- Research Site
-
-
Florida
-
Hialeah、Florida、美国、33012
- Research Site
-
Largo、Florida、美国、33777
- Research Site
-
Orlando、Florida、美国、32825
- Research Site
-
Tampa、Florida、美国、33606
- Research Site
-
-
Georgia
-
Woodstock、Georgia、美国、30189
- Research Site
-
-
Indiana
-
Indianapolis、Indiana、美国、46260
- Research Site
-
-
Maryland
-
Lutherville-Timonium、Maryland、美国、21093
- Research Site
-
-
Mississippi
-
Gulfport、Mississippi、美国、39503
- Research Site
-
Ridgeland、Mississippi、美国、39157
- Research Site
-
-
Missouri
-
Kansas City、Missouri、美国、64111
- Research Site
-
-
Nebraska
-
Omaha、Nebraska、美国、68134
- Research Site
-
-
New Hampshire
-
Portsmouth、New Hampshire、美国、03801
- Research Site
-
-
North Carolina
-
Statesville、North Carolina、美国、28625
- Research Site
-
-
South Carolina
-
North Charleston、South Carolina、美国、29405
- Research Site
-
-
Tennessee
-
Knoxville、Tennessee、美国、37938
- Research Site
-
-
Texas
-
Austin、Texas、美国、78731
- Research Site
-
Dallas、Texas、美国、75230
- Research Site
-
Port Arthur、Texas、美国、77642
- Research Site
-
San Antonio、Texas、美国、78249
- Research Site
-
San Antonio、Texas、美国、78231
- Research Site
-
-
-
-
-
Hull、英国、HU3 2PA
- Research Site
-
Leicester、英国、Le5 4PW
- Research Site
-
Penarth、英国、CF64 2XX
- Research Site
-
Rotherham、英国、S65 1DA
- Research Site
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Adults ≥ 18 years of age
- BMI of (a) ≥ 30 kg/m2, or (b) ≥ 27kg/m2 and have a current diagnosis of at least 1 weight-related comorbidities (treated or untreated)
- A stable body weight for 3 months prior to Screening (±5% body weight change)
Exclusion Criteria:
- Have obesity induced by other endocrine disorders, such as Cushing's syndrome or Prader-Willi syndrome
- Has received prescription or non-prescription medication for weight loss within the last 3 months prior to Screening
- Previous or planned (within study period) bariatric surgery or fitting of a weight loss device (eg, gastric balloon or duodenal barrier)
- History of type 1 diabetes mellitus or T2DM
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:四人间
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Arm 1
Dose 1 |
IMP injected subcutaneously, once a week. Unit dose strength as per CSP |
|
实验性的:Arm 2
Dose 2 |
IMP injected subcutaneously, once a week. Unit dose strength as per CSP |
|
实验性的:Arm 3
Dose 3 |
IMP injected subcutaneously, once a week. Unit dose strength as per CSP |
|
安慰剂比较:Arm 4
Placebo - Dose matched with each Experimental arm |
Placebo matching IMP dose injected subcutaneously, once a week. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Percent change in body weight from baseline to week 26
大体时间:26 weeks
|
To determine whether AZD6234 is superior to placebo for weight loss |
26 weeks
|
|
Weight loss ≥ 5% from baseline weight to week 26
大体时间:26 weeks
|
To determine whether AZD6234 is superior to placebo in participants with weight loss ≥ 5% from baseline |
26 weeks
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Weight loss ≥ 5% from baseline to week 36
大体时间:36 weeks
|
To determine whether AZD6234 is superior to placebo in participants with weight loss ≥ 5% from baseline |
36 weeks
|
|
Weight loss ≥ 10% from baseline to week 36
大体时间:36 weeks
|
To determine whether AZD6234 is superior to placebo in participants with weight loss ≥ 10% from baseline |
36 weeks
|
|
Percent change in body weight from baseline to week 36
大体时间:36 weeks
|
To determine whether AZD6234 is superior to placebo for weight loss |
36 weeks
|
|
Absolute change in body weight (kg) from baseline to week 26 and week 36
大体时间:week 26 and week 36
|
To determine whether AZD6234 is superior to placebo for absolute weight loss |
week 26 and week 36
|
|
AZD6234 plasma concentrations
大体时间:Week 43
|
To characterise the PK of AZD6234 |
Week 43
|
合作者和调查者
赞助
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- D8750C00004
- 2024-514000-13-00 (注册表标识符:EU CT number)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
IPD 共享时间框架
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD 共享访问标准
When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
IPD 共享支持信息类型
- 研究方案
- 树液
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.